PROBILIFT L Drops

For Lactose Intolerance

6-Strain Probiotic + Lactase

Probiotics are beneficial bacteria essential for improving intestinal health.
ProbiLIFT L is a probiotic supplement specifically formulated with 6 probiotic strains and lactase.

What does ProbiLIFT L do?

  • Breaks down lactose to reduce the symptoms of lactose intolerance

  • Assists infants in digesting lactose, preventing flatulence, vomiting,
    diarrhoea, and long periods of restlessness and crying.

  • Fights the growth of harmful bacteria

  • Supports the immune system

  • Increases the levels of beneficial bacteria in the gut

ProbiLIFT L can replace the good bacteria lost through:

  • Antibiotic treatment3

  • Diarrhoea & Constipation7,8

  • GI infection10

  • Old age6

  • Malnutrition

ProbiLIFT L can assist in:

  • Reducing the side effects of antibiotic treatment3

  • Minimising GI discomfort and bloating associated with IBS (irritable bowel syndrome), IBD (inflammatory bowel disease) & colitis (intestinal inflammation)4,5

  • Prevention and treatment of allergic skin reactions and eczema9

Why 6 strains?

The beneficial effects of probiotics are both strain-and dose-specific. A combination of various probiotic strains working together has been shown to be the most effective in the gut1. In addition, more significant results can be achieved with multiple strains in combination compared to single strain preparations2.

How to Use:

If you are taking antibiotics, you may increase the dose to 1 ml three times daily for the duration of the course of antibiotics and up to three days after the course is finished. Do not administer probiotics and antibiotics simultaneously. 

Preservative, sugar, flavouring and colourant free.

Do not exceed the recommended daily dosage.
Shake the bottle well before use.

Always tell your healthcare professional if you are taking other medicines on a regular basis, including complementary or traditional medicines.
Safety for use during pregnancy and lactation has not been established.

Porphyria: Safety has not been established.
Do not use when known sensitivity or allergy exists towards any of the ingredients.

STORE OUT OF SIGHT AND REACH OF CHILDREN
This medicine has not been evaluated by the South African Health Product Regulatory Authority (SAHPRA) for its efficacy and intended use.
This medicine is not intended to diagnose, treat, cure or prevent any disease.

DOSAGE AND DIRECTIONS FOR USE:
Babies and children up to 12 years:
Use 1 ml with every feed or meal. Give 1 ml just before breastfeeding. Add 1 ml to the prepared formula feed.
Adults:
Add 1 ml to a lactose-containing foodstuff and consume immediately.

INGREDIENTS:  Active substances per 1 ml:
1 billion CFU* probiotics consisting of a blend of:
Bifidobacterium lactis BI-07® 200 million CFU
Bifidobacterium longum BI-05® 150 million CFU
Lactobacillus acidophilus La-14® 200 million CFU
Lactobacillus reuteri 1E1 150 million CFU
Lactobacillus rhamnosus Lr-32® 150 million CFU
Lactobacillus salivarius Ls-33® 150 million CFU

Tolerase® L (lactase)

1 500 ALU**/ml

*CFU – Colony Forming Units
** Acid Lactase Unit

Tolerase® L is a trademark of DSM.
Inactive Ingredients: Medium Chain Triglyceride (MCT) oil and silicon dioxide.

Detailed Information:

Scheduling status: S0. Proprietary name (and dosage form): PROBILIFT L (capsules). Pharmacological classification: D.34.9 Probiotic. Complementary Medicine. Health Supplement. Pharmacological action: Probiotics are beneficial bacteria, essential for improving intestinal health. PROBILIFT L is a probiotic supplement specially formulated with 6 probiotic strains and lactase. Probiotics can increase the levels of beneficial bacteria in the gut, creating an environment that is unfavourable to the growth of harmful bacteria. By introducing live probiotic cultures, like what is contained in PROBILIFT L to the intestinal tract, the beneficial gut flora populations are increased and transitory flora, including pathogenic or bad bacteria, are not able to colonise the intestine. PROBILIFT L contains the enzyme lactase, a naturally occurring enzyme that helps the body to break down the complex sugar lactose, found in milk, breastmilk, some infant formulas and dairy products. Infants may have difficulty digesting lactose, resulting in trapped wind and flatulence, vomiting, diarrhoea, and long periods of restlessness and crying. PROBILIFT L helps the body to digest lactose and manage symptoms of lactose intolerance. PROBILIFT L has been specially formulated to assist with the symptoms of lactose intolerance. Probiotics should normalise the microbial balance in the human intestines when ingested on a regular basis thereby supporting the functioning of the digestive tract. Identification: PROBILIFT L contains a cream coloured liquid with white suspended particles. Presentation PROBILIFT L is packed in a 30 ml amber glass bottle containing 30 ml of liquid, with a black plastic tamper evident cap and a graduated glass pipette. Each carton contains 1 blister strip. Agera Health. info@agerapharma.co.za. www.agerahealth.co.za. 30 ml.

Resources:

  1. Timmerman, H. M., Koning, C. J., Mulder, L., Rombouts, F. M., Beynen, A. C. (2004). Monostrain, multistrain and multispecies probiotics: a comparison of functionality and efficacy. International Journal of Food Microbiology, 96(3), 219-233.
  2. Leyer, G. J., Li, S., Mubasher, M. E., Reifer, C., Arthur C. Ouwehand, A. C. (2009). Probiotic Effects on Cold and Influenza-Like Symptom Incidence and Duration in Children. Pediatrics, 124, 172-179.
  3. Kyne, L., Kelly, C. P. (2001). Recurrent Clostridium difficile diarrhoea. Gut, 49, 152–153.
  4. Ringel, Y., Ringel-Kulka, T., Maier, D., Carroll, I., Galanko, J. A., Leyer, G., Palsson, O. S. (2011). Clinical trial: Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients with Functional Bowel Disorders – a Double-Blind Study. Journal of Clinical Gastroenterology, 45(6), 518–525.
  5. Van der Kleij, H., O’Mahony, C., Shanahan, F., O’Mahony, L., Bienenstock, J. (2008). Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. American Journal of Physiology- Regulatory, Integrative & Comparative Physiology, 295, 1131–1137.
  6. Biagi, E., Candela, M., Fairweather-Tait, S., (2012). Aging of the human metaorganism: the microbial counterpart. Age, 34, 247–267.
  7. Sazawal, S., Hiremath, G., Dhingra, U., Malik, P., Deb, S, Black, R. E. (2006). Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. The Lancet Infectious Diseases, 6(6), 374 –382.
  8. Guandalini, S. (2006). Probiotics for children: use in diarrhea. Journal of Clinical Gastroenterology, 40(3), 244–248.
  9. Rautava, S., Kalliomaki, M., Isolauri, E. (2005). New therapeutic strategy for combating the increasing burden of allergic disease: probiotics: a Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. Journal of Allergy & Clinical Immunology, 116(1, 31–37.
  10. Fooks, L. J., Fuller, R., Gibson, G. R. (1999). Prebiotics, probiotics and human gut microbiology. International Dairy Journal, 9, 53-61.
  11. Binns, N. (2013.) Probiotics, Prebiotics and the Gut Microbiota. ILSI Europe Concise Monograph Series.